NYSE$AMRX
Amneal Pharmaceuticals Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Amneal's financial performance decreased due to lower revenue and gross margins, partially offset by cost savings.
Amneal Pharmaceuticals reported a decrease in net revenue and earnings for Q4 2019 compared to the prior year period. Net revenue was $397 million, a decrease of 20%. Net loss was $32 million, and diluted EPS was a loss of $0.23. Adjusted EBITDA was $81 million, and adjusted diluted EPS was $0.08.
- Net revenue decreased by 20% to $397 million due to lower Generics business revenue.
- Net loss attributable to Amneal Pharmaceuticals was $32 million compared to a net loss of $9 million in the prior year period.
- Adjusted EBITDA decreased by 57% to $81 million due to lower revenue and gross margins.
- Adjusted diluted EPS was $0.08, compared to $0.33 for the prior year period.
Headline financials
Revenue & EPS history
Amneal · Revenue · Quarterly
$397M
Revenue by segment
Amneal · $397M total across 2 segments · Q4 2019
- Affordable Medicines$300M—75.6%
- Specialty$97M—24.4%
Forward guidance
Amneal's full year 2020 estimates, which include the impact of our January 31, 2020 transaction with AvKARE, Inc. and its related affiliate doing business as R&S Northeast LLC, are based on management's current expectations, including with respect to prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events.
Tailwinds
- Net revenue $1,875 million - $1,975 million
- Adjusted gross margin 44% - 46%
- Adjusted EBITDA $400 million - $450 million
- Adjusted diluted EPS $0.45 - $0.60
- Operating cash flow $150 million - $200 million
Headwinds
- Capital expenditures $60 million - $70 million
- Weighted average diluted shares outstanding Approximately 300 million
- The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable GAAP measures without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation.
- The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments and other gains and losses.
- These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.6%
Avg return
Earnings day
-3.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
54%
20 / 37 earnings
Positive
+36.6%
Q2 2023
Best reaction
-23.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -7.6% | +0.9% | |
| Q4 2025 | -4.6% | -8.2% | -18.2% | |
| Q3 2025 | -4.1% | +8.8% | +20.0% | |
| Q1 2025 | +3.0% | -6.7% | -5.4% | |
| Q4 2024 | +3.5% | +7.0% | -1.2% | |
| Q3 2024 | +6.9% | +4.9% | -1.9% | |
| Q2 2024 | +12.9% | +9.6% | +21.9% | |
| Q1 2024 | +7.1% | +6.1% | +7.6% | |
| Q4 2023 | -2.2% | -3.8% | +9.8% | |
| Q3 2023 | -3.6% | +0.2% | +11.4% | |
| Q2 2023 | +36.6% | +25.9% | +25.6% | |
| Q1 2023 | +9.8% | -3.3% | +38.6% | |
| Q4 2022 | -8.1% | -15.8% | -33.5% | |
| Q3 2022 | +13.0% | +8.2% | +16.8% | |
| Q2 2022 | -9.5% | -9.2% | -36.4% | |
| Q1 2022 | -11.5% | -22.2% | -13.0% | |
| Q4 2021 | -7.0% | -12.4% | -3.4% | |
| Q3 2021 | -12.5% | -9.8% | -29.0% | |
| Q2 2021 | +4.5% | +4.9% | +6.6% | |
| Q1 2021 | -8.1% | -8.0% | -5.5% | |
| Q4 2020 | +5.9% | +0.0% | +40.1% | |
| Q3 2020 | -15.0% | -15.6% | -14.6% | |
| Q2 2020 | -16.3% | -19.9% | -30.7% | |
| Q1 2020 | +20.3% | +16.1% | +42.5% | |
| Q4 2019 | -20.4% | -16.4% | -37.0% | |
| Q3 2019 | -23.0% | -23.0% | +7.0% | |
| Q2 2019 | -8.0% | -10.5% | -18.5% | |
| Q1 2019 | -20.7% | -31.0% | -41.8% | |
| Q4 2018 | +8.4% | +2.0% | +13.8% | |
| Q3 2018 | +5.1% | +4.6% | -9.1% | |
| Q2 2018 | +0.6% | +9.8% | +19.4% | |
| Q1 2018 | +1.5% | +13.3% | +30.2% | |
| Q4 2017 | +4.4% | — | — | |
| Q3 2017 | +5.9% | — | — | |
| Q2 2017 | +1.5% | — | — | |
| Q1 2017 | -3.2% | — | — | |
| Q4 2016 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro